DUN T1
Orally Administered Drug for Type-1 Diabetes
Startup Seed Health Tech & Life Sciences Est. 2017
🌐 WebsiteLinkedIn
Total Raised
$45K
Seed
Last Round
$45K
1 rounds
Investors
1
1 public
Team
3
1-10 employees
Confidence
85/100
Patents
1
About
DUN T1 is an early-stage R&D company that develops an orally administered drug for type 1 diabetes. DUN T1's vision is to develop a proactive approach towards treatment and early diagnosis. DUN T1's novel natural ingredient is patented, safe, and effective.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target Customer
Commerce & RetailDistribution ChannelsDistributorHealthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business Model
B2B2C
Tags
patientschildrenpharma-companiespharmaceuticalsdrug-discoverychronic-patientschronic-diseasetreatmentsnatural-active-ingredientsdiabetesoral-drugs
Funding & Events
Dec 2019
Equity crowdfunding $45K
Fundit
Details
Product Stage
R&D
Employees
1-10
Exact Count
3
District
Center District
Founded
2017
Registrar
516033875
Locations
HaDuhifat Street 34, Meishar, Israel
Links
Website
www.dunica.info/
LinkedIn
Profile
Admin
Last Update
Dec 4, 2021
Verified by
Yotam Maman
Missing
news, not claimed, markets
Team (3)
Daniella Givon
CEO & Head of R&D
Founder
Raanan Margalit
Head of Pre-Clinical Studies
Founder
Nadav Shraibom
Head of Strategy Affairs
Founder
Internal
Created by
Yotam Maman (yotamm1988@gmail.com)
Created
2021-06-02T00:00:00.000Z
Last editor
Yotam Maman (yotamm1988@gmail.com)
Finder · DUN T1 · 2026